Welcome to our dedicated page for NEOGENOMICS SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics Inc. President & Chief Operating Officer Warren Stone reported an equity compensation event on April 1, 2026. He exercised 17,562 restricted stock units into an equal number of shares of common stock at an exercise price of $0.00 per share.
Of these shares, 6,911 were disposed of through a tax-withholding transaction to satisfy tax obligations, a non-market event. Following these transactions, Stone directly holds 158,365 shares of NeoGenomics common stock, along with multiple outstanding stock option, restricted stock unit, and performance stock unit awards as listed in the filing.
NeoGenomics Inc. Chief Executive Officer Anthony P. Zook exercised equity awards and settled related taxes using shares. On April 1, 2026, he converted 140,498 restricted stock units into the same number of common shares at a $0.00 exercise price. Of these, 45,453 common shares were withheld to cover tax obligations, leaving 133,111 common shares held directly after the transactions, plus 18,900 shares held indirectly through the Amended and Restated Anthony P. Zook Living Trust. He also continues to hold substantial stock options and restricted stock units granted in 2025 and 2026 that vest ratably over three years and have premium exercise prices based on 110% of the stock’s closing prices on the respective grant dates.
NeoGenomics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned of NeoGenomics common stock following an internal realignment.
The filing explains subsidiaries and business divisions of The Vanguard Group now report separately in reliance on SEC Release No. 34-39538, and Vanguard states it holds 0% of the class.
NeoGenomics Inc. Chief Accounting Officer Greg D. Aunan reported equity awards received on March 1, 2026. He was granted 36,825 stock options and 22,889 restricted stock units (RSUs), both with an exercise or acquisition price of $0.00 per share.
The stock options and RSUs each vest ratably over the first three anniversary dates of the grant date, meaning the awards vest in three equal annual installments. Once vested and settled into common shares, the shares of common stock are not subject to expiration. The filing also updates his directly owned option, RSU, and common stock balances as of the same date.
NeoGenomics Inc. executive vice president and general counsel Alicia C. Olivo reported new equity awards. On March 1, 2026, she received 147,804 stock options and 89,013 restricted stock units as compensation, both granted at an exercise/issue price of $0.00 per share.
The stock options are described as premium-price options, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest in equal installments over the first three anniversaries of the grant date, and once vested, the related common shares are not subject to expiration.
NeoGenomics Inc. reported that President & Chief Operating Officer Warren Stone received new equity awards. On March 1, 2026, he was granted 253,378 stock options and 152,594 restricted stock units, both vesting ratably over the first three anniversary dates of the grant.
The stock option grant was structured as a premium-price option, with the exercise price set at 110% of the February 27, 2026 closing share price. Footnotes also describe Mr. Stone’s existing stock options, restricted stock units, and performance stock units granted between 2022 and 2025, which vest over multi‑year and performance-based schedules.
NeoGenomics Inc. reported that Chief Executive Officer Anthony P. Zook received new equity awards. On March 1, 2026, he was granted 675,676 stock options and 406,918 restricted stock units at no cost per unit. The options are premium-price awards, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest ratably over the first three anniversaries of the grant date, tying most of the value to multi‑year service and performance. Once vested, the underlying common shares are not subject to expiration. Footnotes also reference earlier premium-price grants on April 1, 2025, indicating a continuing emphasis on performance-oriented, at-risk compensation for the CEO.
NeoGenomics Inc. Chief Financial Officer Abhishek Jain reported his initial equity holdings. On January 13, 2026, he was granted 183,578 stock options and 110,088 restricted stock units, which vest ratably over the first three anniversaries of the grant date. Once vested, the underlying common shares are not subject to expiration.
NeoGenomics President & Chief Operating Officer Warren Stone reported equity award vesting and related share-withholding transactions. On February 21 and 23, 2026, restricted stock units converted into 36,548 shares of common stock at no cash exercise price.
To cover tax obligations tied to these RSU releases, 10,465 common shares were disposed of through issuer share withholding rather than open-market sales. Following these transactions, Stone directly owned 147,714 shares of NeoGenomics common stock, along with various stock option, restricted stock unit, and performance stock unit holdings described in the filing footnotes.
NeoGenomics Chief Financial Officer Jeffrey Scott Sherman reported equity award activity, not open‑market trading. On February 21 and February 23, he converted restricted stock units into common stock in transactions coded as exercises or conversions. The filing also shows shares withheld and disposed of to cover tax obligations related to these RSU releases. After these transactions, he directly owned 220,009 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that vest over future years.